Application status and future prospects of proton therapy for pediatric medulloblastoma
10.3969/j.issn.1005-202X.2025.09.001
- VernacularTitle:儿童髓母细胞瘤质子治疗现状和展望
- Author:
Jiayu FAN
1
;
Xuanni WEI
;
Chenxi LI
;
Zeru WANG
;
Xiaoyan HUANG
;
Sijuan HUANG
;
Yuanyuan CHEN
;
Xin YANG
Author Information
1. 华南恶性肿瘤防治全国重点实验室/广东省鼻咽癌诊治研究重点实验室/广东省恶性肿瘤临床医学研究中心/中山大学肿瘤防治中心放疗科,广东 广州 510060;广州新华学院生物医学工程学院,广东 广州 510520
- Publication Type:Journal Article
- Keywords:
children;
medulloblastoma;
proton therapy;
review
- From:
Chinese Journal of Medical Physics
2025;42(9):1121-1129
- CountryChina
- Language:Chinese
-
Abstract:
Objective To conduct a comprehensive review on application status and future development prospects of proton therapy for pediatric medulloblastoma.Methods A total of 218 literatures were retrieved from PubMed and CNKI database using the search terms"pediatric medulloblastoma,proton therapy,radiotherapy"(English)and"儿童髓母细胞瘤,质子治疗,放射治疗"(Chinese),with a publication timeframe from January 1,2004,to June 1,2025.Inclusion criteria were as follow:(1)proton therapy for pediatric medulloblastoma;(2)radiotherapy for pediatric medulloblastoma;(3)proton therapy for pediatric brain tumors;(4)development and applications of proton therapy.Exclusion criteria were as follow:(1)outdated literatures;(2)redundant or highly similar studies.After screening,89 literatures met the inclusion criteria.Results Compared with conventional treatments such as surgery,photon therapy,and chemotherapy,proton therapy for pediatric medulloblastoma significantly reduced acute toxicity and long-term side effects including cognitive dysfunction,endocrine disorders,and hearing loss.Additionally,proton therapy exhibited favorable cost-effectiveness.In the future,the therapeutic outcomes would be further enhanced through the optimization of proton therapy techniques,treatment planning,and equipment.Conclusion With ongoing technological advancements and growing clinical experience,proton therapy is expected to become one of the standard treatment modalities for pediatric medulloblastoma.
